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Severe Hypoglycemia and
Cognitive Decline in Older People
With Type 2 Diabetes: The
Edinburgh Type 2 Diabetes Study
OBJECTIVE
People with type 2 diabetes are at increased risk of age-related cognitive decline
and dementia. Hypoglycemia is a candidate risk factor, but the direction of as-
sociation between episodes of severe hypoglycemia and cognitive decline in type
2 diabetes remains uncertain.
RESEARCH DESIGN AND METHODS
In the Edinburgh Type 2 Diabetes Study, cognitive function was assessed in 831
adults with type 2 diabetes (aged 60–75 years) at baseline and after 4 years. Scores
on seven neuropsychological tests were combined into a standardized general
ability factor g. Self-reported history of severe hypoglycemia at baseline (history
of hypoglycemia) and at follow-up (incident hypoglycemia) was recorded.
RESULTS
A history of hypoglycemia was reported by 9.3% of subjects, and 10.2% reported
incident hypoglycemia. Incident hypoglycemia was associated with poorer cog-
nitive ability at baseline (age- and sex-adjusted odds ratio for lowest tertile of
g 2.04 [95% CI 1.25–3.31], P = 0.004). Both history of hypoglycemia and incident
hypoglycemia were also associated with greater cognitive decline during follow-
up (mean follow-up g adjusted for age, sex, and baseline g20.25 vs. 0.03 [P = 0.02]
and20.28 vs. 0.04 [P = 0.01], respectively), including after addition of vascular risk
factors and cardiovascular and microvascular disease to the models (20.23 vs.
0.03 [P = 0.04] and 20.21 vs. 0.05 [P = 0.03], respectively).
CONCLUSIONS
The relationship between cognitive impairment and hypoglycemia appeared
complex, with severe hypoglycemia associated with both poorer initial cognitive
ability and accelerated cognitive decline.
Diabetes Care 2014;37:507–515 | DOI: 10.2337/dc13-1384
Type 2 diabetes is associated with an increased risk of cognitive impairment, age-
related cognitive decline, and dementia (1). Given the increasing numbers of elderly
people with type 2 diabetes in the general population, the identiﬁcation of
potentially modiﬁable risk factors and the prevention of cognitive decline during
older age in this group are of major importance to public health. Although the
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mechanisms underlying progressive
cognitive impairment are likely to be
multifactorial (2), cerebral insults
associated with diabetes-associated
episodes of severe hypoglycemia (those
in which a patient requires external
assistance to aid recovery) are possible
contributors. In studies of individuals
with type 1 diabetes, in whom relatively
frequent episodes of severe
hypoglycemia are well-recognized,
severe hypoglycemia has been
associated with lower cognitive ability
and implicated in provoking cognitive
decline in children (3) but not in adults
(4). However, severe hypoglycemia is
also relatively common in adults with
insulin-treated type 2 diabetes and to a
lesser extent in individuals treated with
sulfonylureas (5). Because type 2
diabetes is predominant in the older
population, the investigation of the
relationship between hypoglycemia and
age-related cognitive decline in this
group, which has received limited
attention, is particularly pressing.
Retrospective analyses of hospital
records have suggested that exposure to
one or more episodes of severe
hypoglycemia is associated with an
increase in the subsequent risk of
dementia in people with type 2 diabetes
(6–9). These ﬁndings may be inﬂated by
the higher incidence of hypoglycemia in
hospital inpatients than in patients in
community settings (10) but are
supported by observations of cross-
sectional links between a history of
severe hypoglycemia and impaired
cognitive function short of frank
dementia (11,12). However, the extent
to which these associations are
explained by hypoglycemia occurring
as a consequence of poor cognitive
ability leading to suboptimal glycemic
control (13) as opposed to
hypoglycemia preceding and possibly
causing decrements in cognitive ability
is unknown. The very few prospective
analyses performed to date (which
might help to resolve this question)
have not implicated severe
hypoglycemia as a risk factor for
negative cognitive outcome (14–16).
However, these studies either have
neglected relatively mild cognitive
decline (14) or have been part of
randomized controlled trials in which
the nature of the intervention itself
potentially affected the relationship
between severe hypoglycemia and
cognitive ability (15,16). The principal
aim of the current study was to
determine the association of both
prevalent and incident severe
hypoglycemia with cognitive decline
measured prospectively through a range
of age-sensitive cognitive tests in a
representative sample of older adults
with type 2 diabetes living
independently in the general population
and participating in a well-established
observational epidemiological study
(the Edinburgh Type 2 Diabetes Study
[ET2DS]).
RESEARCH DESIGN AND METHODS
Study Population
Recruitment and examination
procedures for the prospective ET2DS
have been reported previously (17). In
brief, in 2006/2007, a sample of 1,066
men and women with type 2 diabetes
(aged 60–75 years), largely representative
of all individuals invited at random
froma population-based diabetes register
(18), attended a baseline clinic. In 2010/
2011, 831 participants (attenders)
returned for a 4-year follow-up;
nonattenders were followed up
through postal questionnaires, linkage
to hospital records, death certiﬁcate
data, and review of hospital notes. All
participants gave written informed
consent.
Clinical Examination
At the baseline clinic and year-4 follow-
up, HDL cholesterol, total cholesterol,
and plasma HbA1c concentrations were
measured in fasting blood samples;
systolic and diastolic brachial blood
pressures were measured; and smoking
history (current, never, and former) was
self-reported. Diabetic retinopathy was
assessed at baseline as absent, mild, or
moderate/severe on the basis of seven-
ﬁeld retinal photographs. History of
myocardial infarction (MI), angina,
stroke, and transient ischemic attack
(TIA) was determined at baseline
through self-report of a physician
diagnosis, World Health Organization
chest pain questionnaire, 12-lead
electrocardiogram, and linkage to
hospital discharge records, as detailed
previously (18). The same sources of
data and criteria were used to ascertain
incident MI, angina, stroke, and TIA
events between baseline and year 4.
Scores on the self-administered
depression subscale of the Hospital
Anxiety and Depression Scale (HADS-D)
(19) (score range 0–21) measured
symptoms of depression at baseline and
at year 4. Scores,24 of 30 on the Mini-
Mental State Examination (20) were
used together with additional criteria
(21) to identify participants with
dementia by year 4 follow-up.
Measurement of Hypoglycemia
Reporting of severe hypoglycemia in the
ET2DS is summarized in Fig. 1. At
baseline, a questionnaire determined
participants’ history of severe
hypoglycemia (history of hypoglycemia),
which was deﬁned as an episode of
hypoglycemia requiring the assistance
of another person to effect recovery.
Participants were asked about the
number of episodes they had
experienced over their lifetime and
within the past year. A similar
questionnaire at the year 4 examination
determined severe hypoglycemia since
baseline (incident hypoglycemia),
including the number of episodes
experienced in total, and in the year
preceding the examination. Data from
participants who expressed uncertainty
were not used.
Additionally, 898 consenting participants
were enrolled in a detailed 6-month
survey of severe hypoglycemia,
commencing ;1 year after baseline.
Once every 2 months for a total of
6 months, participants returned self-
completed questionnaires based on the
Edinburgh Hypoglycemia scale (22) that
comprised items on symptoms, date
and time of any hypoglycemic episode,
loss of consciousness, help from
another person, treatment, and blood
glucose values, if measured. For those
who reported severe hypoglycemia or
who failed to return a questionnaire,
data were obtained and veriﬁed by
telephone.
Cognitive Assessment at Baseline and
Year 4
With the aim to minimize effects of
measurement error on the baseline and
year 4 cognitive test data (a prerequisite
for the validity of analyses of cognitive
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change), conditions for cognitive testing
were kept the same at the two time
points asmuch as possible. At both times,
the absence of current hypoglycemia
was conﬁrmed by measuring blood
glucose before commencing each
testing session, which was only
undertaken if values were$4.0 mmol/L.
Participants were also reminded by
letter to bring their glasses or hearing
aids as required and were prompted to
use these at the clinic. Data from
participants with severe sensory
impairment were not used. The Logical
Memory (LM) and Faces subtests of the
Wechsler Memory ScaledThird
Edition (U.K.) assessed verbal and
nonverbal memory, respectively (23).
Executive function was measured with
the Borkowski Verbal Fluency Test
(BVFT) and the Trail Making Test B
(TMT-B). The Digit SymboldCoding
(DSC), Letter-Number Sequencing
(LNS), and Matrix Reasoning (MR)
subtests of the Wechsler Adult
Intelligence ScaledThird Edition (U.K.)
assessed speed of processing, working
memory, and nonverbal reasoning,
respectively (24). Peak premorbid
ability was estimated by the junior and
senior Mill Hill Vocabulary Scale (MHVS)
(25), a valid measure of crystallized
intelligence relatively immune to
age-related decline (26).
Statistical Analysis
TMT-B, HADS-D, and duration of
diabetes were transformed to their
natural logarithms because of skewed
distributions. Data were missing on the
seven age-sensitive cognitive tests (LM,
Faces, MR, DSC, TMT-B, LNS, BVFT) for
between 0.6% (BVFT) and 1.7% (LNS) of
participants at baseline and for between
0.8% (MR) and 4.7% (LNS) at year 4
follow-up. Multiple imputation
accounting for age and sex was carried
out for participants withmissing data on
one, two, or three cognitive tests.
Different cognitive tests tending to load
on a single factor of global cognitive
ability, which has been termed g (27), is
commonly observed. With the aim to
extract g, components with eigenvalues
.1 were extracted from a principal
components analysis of scores on the
seven cognitive tests after their
imputation. All seven cognitive tests
loaded on a single component with an
eigenvalue .1; inspection of the scree
plot also suggested a strong general
cognitive ability factor. The use of the
standardized factor g derived from this
method is advantageous because in
contrast to scores on individual
cognitive tests, it partly offsets test-
speciﬁc measurement error. In the
ET2DS, g has been found to capture
participants’ overall performance at
baseline and year 4 follow-up, as
described previously (21).
All analyses were adjusted for age and
sex. Initially, ANCOVA was used to
compare mean baseline g between
individuals with incident hypoglycemia
and the remaining sample. This method
does not entirely eliminate the inﬂuence
from potential confounders to allow
their dismissal, especially in
observational studies, but reduces
Figure 1—Reporting of severe hypoglycemia (SH) in the ET2DS.
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covariate-associated noise in the data
(28); therefore, it was used to address
the issue of confounding in the current
study. Additionally, odds ratios (ORs) for
incident hypoglycemia were calculated
in participants with low baseline g (i.e.,
who scored in the lowest tertile of g) in
logistic regression models. Analyses
were repeated with restriction to
incidence of ﬁrst-ever incident
hypoglycemia.
Further logistic regression analyses
ascertained the OR for reduced follow-
up g and accelerated decline in g (both
scoring in the lowest tertiles of
distribution) according to history of
previous hypoglycemia at baseline and
of subsequent incident hypoglycemia
between baseline and year 4.
Additionally, ANCOVA was used to
determine hypoglycemia associations
with follow-up cognitive test performance
and cognitive change. Cognitive change
between baseline and year 4 was
represented by inclusion of baseline
cognitive test scores in the models of
follow-up scores. This method was
chosen over the alternative of raw
change scores because its parameter
estimates are more straightforward and
no assumptions are made regarding the
group difference in cognitive function at
baseline (29).
Cognitive change between estimated
peak premorbid ability and year 4 ability
was represented by inclusion of baseline
MHVS in models of year 4 cognitive test
scores. For all outcomes, vascular risk
factors (HDL and total cholesterol,
systolic and diastolic blood pressure,
smoking), HbA1c, cerebrovascular
disease (stroke, TIA), coronary heart
disease (angina, MI), and diabetic
retinopathy as a measure of
microvascular disease (vascular
covariates) were then added to the
models. Treatment modality, duration
of diabetes, and HADS-D were also
included in analyses performed post hoc
and presented in the text. Baseline
covariates were used for analyses of a
baseline history of hypoglycemia, and
year 4 covariates were used in analyses
of incident hypoglycemia. An exception
to this was smoking status, which was
found to be relatively stable over the
course of the study, and retinopathy,
which was measured only at baseline.
Analyses were performed with SPSS
version 19.0 (IBM Corporation, Armonk,
NY) statistical software.
RESULTS
Characteristics of Follow-up Study
Population
Characteristics of attenders of the year 4
follow-up are presented in Table 1.
Attenders were largely similar to
nonattenders in terms of baseline
clinical characteristics but had higher
baseline cognitive function (21). In
addition, nonattendance was
signiﬁcantly associated with a baseline
history of hypoglycemia (31.3 and 20.5%
of participants with and without a
history of hypoglycemia at baseline,
respectively, were nonattenders; P =
0.01).
History of Hypoglycemia
In the total study population attending
follow-up (n = 831), 77 (9.3%)
participants reported a history of
hypoglycemia at baseline and 85
(10.2%) experienced incident
hypoglycemia. Of the latter, 27 (31.8%)
also had a baseline history of
hypoglycemia (P , 0.001 for risk of
recurrent severe hypoglycemia). Of 898
participants enrolled in the 6-month
hypoglycemia survey, 30 reported a
total of 45 episodes of severe
hypoglycemia. For 18 of the 45 episodes
in which blood glucose readings were
self-reported, all but 1 of 14
measurements made before treatment
were ,3.0 mmol/L, suggesting that
participants were reasonably accurate
at identifying hypoglycemia. Of the 30
participants reporting hypoglycemia in
the 6-month survey, 25 recovered after
treatment with a glucose drink or
ingesting food, 1 required injection with
glucagon, and 3 required intravenous
glucose (information was missing for 1
participant). Twenty-three of the 30
participants attended the year 4 follow-
up; most (74%) reported incident
hypoglycemia in the 4 years since
baseline, demonstrating a reasonable
level of recall of hypoglycemia at
follow-up.
Association of Baseline Cognitive
Function With Incident Hypoglycemia
Baseline global cognitive function was
lower in participants with incident
hypoglycemia than in those remaining
free of incident hypoglycemia (age- and
sex-adjusted mean g 20.08 [95% CI
20.27 to 0.12] vs. 0.17 [0.10–0.24], P =
0.019). Participants scoring in the
lowest tertile of g were at a twofold
higher risk of experiencing incident
hypoglycemia compared with higher-
scoring participants (age- and sex
adjusted OR 2.04 [95% CI 1.25–3.31],
P = 0.004). Results were largely
unchanged when restricted to
participants who experienced their
ﬁrst-ever severe hypoglycemic episode
during the follow-up period (age- and
sex-adjusted OR 2.45 [1.37–4.39], P =
0.002; adjusted mean g 20.08 [20.33
to 0.16] vs. 0.18 [0.12–0.25], P = 0.038).
The presence of dementia in four
participants was not signiﬁcantly
associated with incident hypoglycemia
(P . 0.05). Because their exclusion did
not alter P values and effect sizes (data
not shown), results are reported for the
entire sample.
Baseline History of Hypoglycemia,
Cognitive Function, and Cognitive
Change
Participants with a history of
hypoglycemia had lower performance
on MR, DSC, TMT-B, and g at year 4
(Table 2) and were marginally more
likely to score in the lowest tertile of g
(age- and sex-adjusted OR 1.65 [0.99–
2.76], P = 0.055) compared with the
remaining population. All associations
persisted when MHVS (which estimates
premorbid ability) was included in the
model (all P , 0.05) (data not shown).
All except DSC (P = 0.145) survived
further addition of baseline vascular
covariates, baseline HADS-D, duration
of diabetes, and baseline treatment
modality into the model (all P , 0.05)
(data not shown).
A history of hypoglycemia was also
associated with a steeper decline
between baseline and year 4 on MR,
TMT-B, and g (Table 2), although the OR
for cognitive decline (lowest tertile
of standardized residuals signifying a
4-year decline in g) was not statistically
signiﬁcant (1.36 [0.82–2.24], P = 0.230).
Inclusion of baseline vascular covariates
marginally attenuated the associations
with MR and g (Table 2). For MR (P ,
0.05) but not g (P = 0.083), the
association remained statistically
signiﬁcant when baseline HADS-D,
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baseline treatment, and disease
duration were added to the model (data
not shown).
Incident Hypoglycemia, Cognitive
Function, and Cognitive Change
Incident hypoglycemia was associated
with lower g, MR, LNS, TMT-B, DSC, and
Faces performance at year 4 (Table 3).
The risk of reduced cognitive function at
follow-up (scoring in the lowest tertile
g) was increased threefold for the
incident hypoglycemia group (age- and
sex-adjusted OR 2.97 [1.82–4.86], P ,
0.001). All associations remained
statistically signiﬁcant when MHVS was
added to the respective models,
suggesting that participants with
incident hypoglycemia experienced a
steeper estimated lifetime decline
between their peak premorbid and
late-life ability than did the group free
of incident hypoglycemia (Table 3). All
associations except for DSC further
survived the inclusion of year 4 vascular
covariates (Table 3) and the inclusion of
HADS-D at year 4, treatment at year 4,
and disease duration in the respective
models (all P, 0.05) (data not shown).
Participants with incident hypoglycemia
also experienced a steeper decline
between baseline and year 4 in MR,
TMT-B, DSC, Faces, and g (Table 3).
Those with the highest rate of decline
(scoring in the lowest tertile of
standardized residuals signifying a
decline in g) were marginally more likely
to have experienced incident
hypoglycemia than the remaining
population (age- and sex-adjusted OR
1.53 [0.95–2.47], P = 0.084). The
associations with decline in MR, TMT-B,
Faces, and g survived inclusion of year 4
vascular covariates (Table 3). The
associationwith decline in Faces andMR
further survived addition of HADS-D at
year 4, treatment at year 4, and disease
duration to the model (both P , 0.05);
for TMT-B and g, the ﬁndings were just
short of statistical signiﬁcance (P = 0.064
and 0.072, respectively) (data not
shown).
CONCLUSIONS
Lower cognitive ability at baseline was
associated with a twofold higher
incidence of severe hypoglycemia over 4
years. In addition, severe hypoglycemia
was associated with a steeper decline in
cognitive function. The latter was
observed when cognitive change was
Table 1—Characteristics of year 4 attenders according to incident hypoglycemia reported at follow-up
All attenders
(maximum n = 831)
Incident hypoglycemia
(maximum n = 85)
No incident hypoglycemia
(maximum n = 730)
P value for difference
or trend*
Age (years) 67.69 6 4.16 66.69 6 4.05 67.79 6 4.17 0.022
Male sex 430 (51.7) 32 (37.6) 939 (53.8) 0.005
Duration of diabetes (years) 6.00 (3.00–11.00) 9.50 (5.25–15.00) 6.00 (300–10.00) ,0.001
Baseline treatment ,0.001
Insulin 6 tablets 139 (16.7) 31 (36.5) 103 (14.1)
Sulfonylureas 6 other tablets 210 (25.3) 28 (32.9) 179 (24.6)
Other tablets 316 (38.0) 19 (22.4) 292 (40.1)
Diet alone 165 (19.9) 7 (8.2) 155 (21.3)
Year 4 treatment ,0.001
Insulin 6 tablets 178 (21.4) 40 (47.1) 133 (18.2)
Sulfonylureas 6 other tablets 255 (30.7) 25 (29.4) 228 (31.2)
Other tablets 283 (34.1) 16 (18.8) 261 (35.8)
Diet alone 115 (13.8) 4 (4.7) 108 (14.8)
Plasma HbA1c (%) 7.39 6 1.13 7.86 6 1.22 7.32 6 1.06 ,0.001
Plasma HbA1c (mmol/mol) 57 6 12.4 62 6 13.3 56 6 11.6 ,0.001
Systolic BP (mmHg) 133 6 16 130 6 15 132 6 16 0.086
Diastolic BP (mmHg) 69 6 9 67 6 6 69 6 9 0.002
Vascular disease
MI 111 (13.4) 12 (14.1) 98 (13.4) 0.860
Angina 222 (26.7) 22 (25.9) 197 (27.0) 0.828
Stroke 44 (5.3) 2 (2.4) 42 (5.8) 0.189
TIA 27 (3.2) 7 (8.2) 19 (2.6) 0.005
Retinopathy 266 (32.0) 33 (39.3) 227 (31.5) 0.150
Total cholesterol (mmol/L) 4.34 6 0.90 4.34 6 0.81 4.32 6 0.90 0.890
HDL cholesterol (mmol/L) 1.29 6 0.36 1.26 6 0.35 1.29 6 0.36 0.351
Smoking status
Current smoker 108 (13.0) 18 (21.2) 88 (12.1) 0.018
Ex-smoker 390 (46.9) 37 (43.5) 349 (47.8) 0.455
Never smoked 333 (40.1) 30 (35.3) 293 (40.1) 0.388
HADS-D 3 (1–6) 5 (2–7) 3 (1–5) ,0.001
MMSE 28.47 6 1.64 28.59 6 1.48 28.51 6 1.57 0.647
Dementia 4 (0.5) 0 (0.0) 2 (0.3) 0.629
MHVS 31.45 6 5.07 30.80 6 4.84 31.63 6 5.07 0.151
Data are mean 6 SD, median (interquartile range), or n (%). Data are from baseline unless otherwise indicated. BP, blood pressure; MMSE, Mini-
Mental State Examination. *Comparing the incident hypoglycemia with the no incident hypoglycemia group.
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measured subsequently to the
hypoglycemic events and, even more
strongly, when the two were occurring
simultaneously during the 4-year
follow-up period. Thus, the results
suggest that the experience of severe
hypoglycemia may be associated with
lesser prior cognitive ability and is a risk
factor for accelerated cognitive decline.
In addition to global cognitive ability
measured by g, associations with
cognitive outcome were most
consistently observed for processing
speed, nonverbal memory, executive
function, and reasoning.
Previous cross-sectional studies
demonstrated a relationship between
hypoglycemia and poorer cognitive
function in people with type 2 diabetes
(11,12,14). However, uncertainty
remains about the reasons for this
association and the direction of any
possible causal relationship between
hypoglycemia and cognitive
decrements. Evidence supports that
people with poorer cognitive ability
may be more susceptible to
hypoglycemia. Lower baseline scores
on a screening instrument for dementia
predicted 5-year incident severe
hypoglycemia in the Action in Diabetes
and Vascular Disease: Preterax and
Diamicron Modiﬁed Release Controlled
Evaluation (ADVANCE) trial (15).
Clinically diagnosed dementia has been
shown to predict a two- to threefold
increased risk of hospital admission or
emergency treatment for hypoglycemia
in the Fremantle Diabetes Study (14)
and in the Health, Aging and Body
Composition Study (9). In the Memory
in Diabetes study of the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD-MIND) trial, lower baseline
cognitive test scores also predicted an
increased risk of a ﬁrst-ever
hypoglycemic episode over 3.5 years of
follow-up (11). These ﬁndings are
consistent with the current study in
which baseline g predicted subsequent
severe hypoglycemia. It is possible that
people with lower or declining cognitive
ability are less able to recognize
hypoglycemia, to treat it appropriately
when it occurs, or to prevent it through
modiﬁcation of diabetes therapy.
Less epidemiological evidence supports
the hypothesis that hypoglycemia may
have a direct or indirect effect on the
brain, resulting in cognitive decrements.
In type 1 diabetes, the balance of
evidence suggests that hypoglycemia
may not affect cognitive function in this
way (30). Incidence of severe
hypoglycemia over 18 years was not
associated with concurrent cognitive
decline in the Diabetes Control and
Complications Trial/Epidemiology of
Diabetes Interventions and
Complications cohort (4), and in a
smaller study, 10-year incidence of
severe hypoglycemia failed to predict
Table 2—Association of baseline history of hypoglycemia with cognitive function at year 4 follow-up and 4-year
cognitive decline
No baseline history
(n = 739)
Baseline history
(n = 77)
P value for group
difference
Effect size of group
difference (partial s2)
Model 1: age, sex
MR 11.76 (11.39 to 12.13) 10.14 (8.97 to 11.31) 0.009 0.008
LNS 8.96 (8.75 to 9.16) 8.33 (7.67 to 8.99) 0.076 0.004
BVFT 37.19 (36.27 to 38.11) 34.63 (31.72 to 37.54) 0.100 0.003
DSC 50.51 (49.53 to 51.49) 46.31 (43.19 to 49.44) 0.012 0.012
ln(TMT-B) 109.84 (106.70 to 113.07) 129.02 (117.68 to 141.60) 0.001 0.013
Faces 69.37 (68.78 to 69.96) 68.70 (66.85 to 70.56) 0.500 0.001
LM 27.28 (26.69 to 27.84) 27.71 (25.86 to 29.56) 0.661 ,0.001
g 0.04 (20.03 to 0.11) 20.26 (20.49 to 20.04) 0.009 0.008
Model 2: age, sex, baseline score
MR 11.75 (11.47 to 12.03) 10.22 (9.34 to 11.11) 0.001 0.013
LNS 8.92 (8.74 to 9.09) 866 (8.10 to 9.22) 0.394 0.001
BVFT 37.04 (36.50 to 37.59) 36.17 (34.45 to 37.89) 0.340 0.001
DSC 50.31 (49.63 to 50.99) 48.31 (46.14 to 50.49) 0.086 0.004
ln(TMT-B) 110.72 (108.20 to 113.18) 119.94 (111.72 to 128.90) 0.036 0.005
Faces 69.40 (68.92 to 69.87) 68.49 (66.98 to 70.00) 0.260 0.002
LM 27.31 (26.85 to 27.77) 27.34 (25.89 to 28.80) 0.966 ,0.001
g 0.03 (20.04 to 0.10) 20.25 (20.48 to 20.02) 0.020 0.007
Model 3*
MR 11.82 (11.53 to 12.11) 10.35 (9.41 to 11.29) 0.004 0.011
LNS 8.95 (8.77 to 9.13) 8.70 (8.12 to 9.29) 0.423 0.001
BVFT 37.33 (36.77 to 37.89) 36.47 (34.65 to 38.30) 0.381 0.001
DSC 50.38 (49.79 to 51.08) 48.73 (46.46 to 51.01) 0.176 0.002
ln(TMT-B) 109.95 (107.45 to 112.51) 117.57 (109.07 to 126.72) 0.097 0.004
Faces 69.52 (69.03 to 70.01) 68.81 (67.21 to 70.41) 0.409 0.001
LM 27.45 (26.98 to 27.91) 27.93 (26.42 to 29.45) 0.549 ,0.001
g 0.03 (20.04 to 0.11) 20.23 (20.47 to 0.01) 0.040 0.006
Data are adjusted mean (95% CI). n = 808–811 for model 1; n = 807–810 for model 2; n = 768–770 for model 3. Means for ln(TMT-B) are geometric
means. *Adjusted for age, sex, baseline score, and baseline data on HDL cholesterol, total cholesterol, systolic blood pressure, diastolic blood
pressure, smoking, HbA1c, stroke, TIA, angina, MI, and retinopathy.
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subsequent levels of cognitive function
(31). However, people with type 1
diabetes typically are younger and
have a lower prevalence of
comorbidities than those with type 2
diabetes (32). In addition, the Diabetes
Interventions and Complications Trial
cohort was atypical in that the
participants had been selected for
having high compliance with treatment
and a low risk of hypoglycemia such that
these ﬁndings may have been affected
by low prevalence of both the risk factor
(hypoglycemia) and the outcome (age-
related cognitive decline). In type 2
Table 3—Association of incident hypoglycemia with cognitive function at year 4 follow-up and with 4-year and estimated
lifetime cognitive decline
No incident hypoglycemia
(n = 730)
Incident hypoglycemia
(n = 85)
P value for group
difference
Effect size of group
difference (partial s2)
Cognitive ability at year 4
Model 1: age, sex
MR 11.82 (11.45 to 12.19) 10.02 (8.92 to 11.12) 0.003 0.011
LNS 9.02 (8.82 to 9.23) 8.00 (7.38 to 8.61) 0.002 0.012
BVFT 37.20 (36.27 to 38.12) 35.34 (32.60 to 38.09) 0.211 0.002
DSC 50.69 (49.70 to 51.67) 46.63 (43.69 to 49.57) 0.011 0.008
ln(TMT-B) 109.29 (106.16 to 112.51) 126.85 (116.28 to 138.52) 0.001 0.013
Faces 69.63 (69.05 to 70.22) 67.08 (65.33 to 68.83) 0.007 0.009
LM 27.42 (26.83 to 28.01) 26.77 (25.00 to 28.54) 0.493 0.001
g 0.07 (0.00 to 0.13) 20.33 (20.53 to 20.12) ,0.001 0.015
Four-year cognitive decline
Model 2*
MR 11.75 (11.47 to 12.04) 10.57 (9.72 to 11.41) 0.009 0.008
LNS 8.97 (8.79 to 9.14) 8.42 (7.89 to 8.94) 0.052 0.005
BVFT 37.15 (36.61 to 37.70) 35.77 (34.14 to 37.40) 0.116 0.003
DSC 50.51 (49.82 to 51.19) 48.21 (46.16 to 50.26) 0.038 0.005
ln(TMT-B) 109.95 (107.55 to 112.51) 119.82 (112.06 to 128.25) 0.019 0.007
Faces 69.59 (69.11 to 70.07) 67.53 (66.11 to 68.96) 0.008 0.009
LM 27.36 (26.90 to 27.83) 27.27 (25.87 to 28.66) 0.900 ,0.001
g 0.04 (20.03 to 0.12) 20.28 (20.49 to 20.06) 0.006 0.009
Model 3†
MR 11.78 (11.49 to 12.07) 10.65 (9.77 to 11.53) 0.017 0.007
LNS 8.98 (8.80 to 9.16) 8.54 (7.99 to 9.09) 0.140 0.003
BVFT 37.32 (36.76 to 37.88) 36.16 (34.46 to 37.86) 0.205 0.002
DSC 50.56 (49.86 to 51.26) 48.79 (46.66 to 50.92) 0.122 0.003
ln(TMT-B) 109.73 (107.23 to 112.28) 119.10 (111.05 to 127.74) 0.029 0.006
Faces 69.69 (69.20 to 70.18) 67.64 (66.15 to 69.12) 0.010 0.009
LM 27.46 (26.99 to 27.94) 27.33 (25.88 to 28.77) 0.860 ,0.001
g 0.05 (20.02 to 0.13) 20.21 (20.43 to 0.01) 0.028 0.006
Estimated lifetime cognitive decline
Model 4‡
MR 11.78 (11.45 to 12.11) 10.30 (9.24 to 11.22) 0.004 0.011
LNS 9.02 (8.83 to 9.21) 8.16 (7.60 to 8.73) 0.006 0.010
BVFT 37.11 (36.26 to 37.96) 35.95 (33.41 to 38.49) 0.394 0.001
DSC 50.61 (49.69 to 51.53) 47.22 (44.46 to 49.98) 0.023 0.007
ln(TMT-B) 109.29 (106.38 to 112.28) 124.71 (114.89 to 135.23) 0.003 0.011
Faces 69.60 (69.03 to 70.17) 67.24 (65.55 to 68.93) 0.010 0.008
LM 27.37 (26.84 to 27.90) 27.36 (25.77 to 28.95) 0.990 ,0.001
g 0.06 (0.00 to 0.12) 20.26 (20.43 to 20.09) 0.001 0.015
Model 5§
MR 11.81 (11.47 to 12.15) 10.28 (9.24 to 11.32) 0.007 0.010
LNS 9.03 (8.84 to 9.23) 8.24 (7.64 to 8.83) 0.013 0.008
BVFT 37.26 (36.94 to 38.13) 36.53 (33.89 to 39.17) 0.608 ,0.001
DSC 50.61 (49.68 to 51.55) 48.22 (45.38 to 51.08) 0.121 0.003
ln(TMT-B) 109.18 (106.17 to 112.28) 122.73 (112.73 to 133.49) 0.010 0.009
Faces 69.70 (69.13 to 70.28) 67.32 (65.56 to 69.08) 0.012 0.008
LM 27.47 (26.93 to 28.01) 27.51 (25.86 to 29.15) 0.963 ,0.001
g 0.07 (0.01 to 0.13) 20.22 (20.39 to 20.04) 0.003 0.012
Data are adjusted mean (95% CI). n = 807–810 for model 1; n = 806–809 for model 2; n = 775–777 for model 3; n = 798–801 for model 4; n = 767–769
for model 5. Means for ln(TMT-B) are geometric means. *Adjusted for age, sex, and baseline score. †Model 2 + baseline smoking, retinopathy, and
year 4 data on HDL cholesterol, total cholesterol, systolic blood pressure, diastolic blood pressure, HbA1c, stroke, TIA, angina, and MI. ‡Adjusted for
age, sex, and baseline MHVS. §Model 4 + baseline smoking, retinopathy, and year 4 data on HDL cholesterol, total cholesterol, systolic blood
pressure, diastolic blood pressure, HbA1c, stroke, TIA, angina, and MI.
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diabetes, one relatively small study
established no links between a baseline
history of severe hypoglycemia and
conversion among normal cognition,
impairment, and frank dementia over 18
months (14). Conversely, some evidence
suggests that the experience of
hypoglycemia may be a risk factor for
future dementia developing in type 2
diabetes (6,7,9). Dementia lies at an end
point of the continuum of age-related
cognitive impairment, and to our
knowledge, the current study has
supplemented the current literature by
providing the most robust evidence to
date that exposure to severe
hypoglycemia either preceding or
concurrent with change in cognition
during aging is associated with an
increase in the rate of age-related
cognitive decline in older people with
type 2 diabetes without frank dementia.
The ﬁnding of a relationship between
hypoglycemia and the memory domain
in particular is consistent with published
evidence for associations of
hypoglycemia with dementia, which
commonly is preceded by memory
impairment (33).
The ﬁndings contrast those of the
ACCORD-MIND and ADVANCE trials in
which patients in intensive treatment
groups (with higher incidence of
hypoglycemia) experienced cognitive
decline at similar rates over 40 months
and 5 years of follow-up, respectively,
compared with the respective standard
treatment groups (15,16). However,
both studies were randomized
controlled trials involving strict glycemic
control and with cognitive function as a
secondary end point. Because
improving glycemic control may
improve cognitive dysfunction when
glycemic control is suboptimal (34),
detrimental effects of hypoglycemia
were potentially counteracted by the
speciﬁc therapeutic interventions. The
ADVANCE trial also assessed cognitive
decline with a screening instrument for
dementia, which is likely to be
insensitive to subtle cognitive changes
(35), and annual incidence of
hypoglycemic episodes (deﬁned on the
basis of criteria comparable to severe
hypoglycemia in the current study) was
low compared with the ET2DS and
ACCORD-MIND trials because none of its
participants were receiving insulin
treatment.
In addition to its prospective nature, the
strengths of the current study lie in the
relatively large size and in the
population being representative of the
full spectrum of people with type 2
diabetes living in the community, with
treatment modalities ranging from diet
to insulin, and with the inclusion of the
age range at which cognitive decline
often becomes apparent. A detailed
battery of validated cognitive tests
covered the major cognitive domains,
and a reasonably comprehensive list of
potential confounders was considered
in the analyses, although, of course,
residual confounding by any
unmeasured variable cannot be ruled
out. Despite potential weakness in the
self-reporting of severe hypoglycemia
given that not all severe episodes
generate symptoms, particularly in
people who have impaired awareness of
hypoglycemia (36), a short prospective
survey embedded into the main study
demonstrated that the participants
appeared to be identifying most, if not
all, episodes at least of symptomatic
severe hypoglycemia and that their
recall (even over a number of years) was
reasonably accurate. Although self-
reported episodes of severe
hypoglycemia may not represent all
episodes of hypoglycemia, including
milder episodes or symptom-free severe
episodes, the measure appears to be a
useful marker of a more generalized risk
of exposure to hypoglycemia. One
limitation of the study, which is inherent
to all observational studies, is the
inability to evaluate the potential for
causality in the reported associations.
Nonetheless, such observational studies
make important contributions to the
understanding of associations and
inform the design of future studies
aimed speciﬁcally at investigating the
issue of causality. The mechanism by
which hypoglycemia could potentially
disrupt cognitive function is unclear.
Although reports of permanent brain
damage or chronic severe cognitive
deﬁcit are rare (37,38), glucose
deprivation has been directly linked to
neuronal death in vitro, and some
evidence in type 1 diabetes suggests
structural differences in the brain
between patients who have and those
who have not been exposed to
hypoglycemia (3).
In the current study, we show that low
cognitive ability is associated with an
increase in the risk of subsequent
episodes of severe hypoglycemia.
Moreover, severe hypoglycemia at
baseline and during follow-up was
associated with an increased risk of
subsequent and/or concurrent cognitive
decline. If the latter association is found
to be causal in nature, it will be
necessary to address the effect of strict
glycemic control on cognitive function
in the clinical management of older
people with type 2 diabetes. In the
meantime, change in cognitive function
should be considered as a clinical end
point in the design of all future
randomized trials of novel antidiabetes
agents that have the potential to induce
or augment the frequency of
hypoglycemia.
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